Press releases - UCB
Nov 14, 2024 · UCB receives U.S. FDA approval for BIMZELX[®] (bimekizumab-bkzx) as the first IL-17A and IL-17F inhibitor for adults with moderate to severe hidradenitis suppurativa Read More
UCB managed 2022 headwinds and is ready for 2023 launches
UCB expects to receive initial feedback for Europe in Q1/Q2 2024. In Q4 2022, UCB initiated a Phase 2a (proof-of-concept) study to evaluate the efficacy and safety of rozanolixizumab to treat adult study participants with severe fibromyalgia syndrome. First topline results are expected in …
Newsroom - UCB
The UCB media relations team responds to calls and emails from professional journalists only.
UCB announces U.S. FDA approvals for BIMZELX[®] (bimekizumab …
Sep 23, 2024 · Brussels (Belgium), September 23, 2024 – 07:00 (CEST) – UCB, a global biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved BIMZELX ® (bimekizumab-bkzx) for the treatment of adults with active psoriatic arthritis (PsA), adults with active non-radiographic axial spondyloarthritis (nr-axSpA ...
UCB announces U.S. FDA approval of ZILBRYSQ[®] (zilucoplan) for …
Brussels (Belgium) 17 October 2023 – UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that ZILBRYSQ ® (zilucoplan) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody ...
UCB - sustaining growth, now and into the future
UCB will continue to advance its late stage development pipeline and prepare upcoming launches to offer potential new solutions for patients. Underlying profitability, adjusted EBITDA, is expected in the range of 27 - 28% of revenue, reflecting the high R&D and …
UCB announces U.S. FDA approval of RYSTIGGO[®] …
Jun 27, 2023 · “We want to thank UCB for their continued commitment to the MG community to bring a new FDA-approved treatment option for generalized myasthenia gravis to patients and their treating physicians,” said Samantha Masterson, President and Chief Executive Officer of the Myasthenia Gravis Foundation of America (MGFA).
UCB and Biogen Announce Positive Topline Results From Phase 3 …
Sep 24, 2024 · UCB and Biogen are advancing dapirolizumab pegol with the objective to address the substantial unmet medical need for people living with SLE, where there are limited treatment options. SLE is a chronic, debilitating autoimmune disease that affects multiple organ systems and disproportionately affects women.
UCB Completes Acquisition of Zogenix, Inc.
Brussels (Belgium), 7 March 2022– 18:00 (CET) - UCB (Euronext: UCB) today announced the successful completion of the previously announced transaction to acquire Zogenix (NASDAQ: ZGNX) for US$ 26.00 per share plus a milestone-based contingent value right for a potential cash payment of US$ 2.00 per share. The total transaction is valued at up ...
UCB expands innovation footprint with new state-of-the-art gene …
Mar 8, 2022 · “From ground-breaking scientific innovation to high-tech manufacturing, our Braine campus is already home to a thriving and dynamic community of scientists, technicians, engineers, and manufacturing personnel,” said Dhaval Patel, Executive Vice President and UCB’s Chief Scientific Officer at UCB.